Loading...
•
Dec 31, 2019
Fate Therapeutics Q4 2019 Earnings Report
Fate Therapeutics' Q4 2019 financial results and operational progress were reported.
Key Takeaways
Fate Therapeutics reported fourth-quarter results, highlighting clinical advancements in its iPSC-derived cancer immunotherapy programs, including FT500, FT516, and FT596, and ended the quarter with $261 million in cash, cash equivalents and marketable securities.
Reported initial clinical data from FT500 Phase 1 study in advanced solid tumors, supporting safety and tolerability of multi-dose treatment paradigm for off-the-shelf, iPSC-derived NK Cells
First patients treated with FT516, the First-ever Engineered iPSC-derived Cellular Immunotherapy, for AML and for B-cell Lymphoma in Combination with Rituximab
Initiated Enrollment of First-in-human Clinical Trial of FT596, the First-ever Cellular Immunotherapy Engineered with Three Active Anti-tumor Modalities
Ended Quarter with $261 Million in Cash, Cash Equivalents and Marketable Securities
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
In 2020, the company looks forward to additional clinical data from its FT500 and FT516 programs, and initial clinical data from FT596. The company also expects to begin clinical investigation of its off-the-shelf, iPSC-derived NK cell programs in multiple myeloma with planned IND submissions for FT538 and for FT576.